Loading...
Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia
Ibrutinib and idelalisib are kinase inhibitors that have revolutionized the treatment of chronic lymphocytic leukemia (CLL). Capable of inducing durable remissions, these agents also modulate the immune system. Both ibrutinib and idelalisib abrogate the tumor-supporting microenvironment by disruptin...
Na minha lista:
| Udgivet i: | Leuk Lymphoma |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6237652/ https://ncbi.nlm.nih.gov/pubmed/29764250 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2018.1457147 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|